The development of PARP inhibitors in ovarian cancer: from bench to bedside

The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olapar...

Descripción completa

Detalles Bibliográficos
Autor principal: Drew, Yvette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816267/
https://www.ncbi.nlm.nih.gov/pubmed/26669452
http://dx.doi.org/10.1038/bjc.2015.394
_version_ 1782424680906358784
author Drew, Yvette
author_facet Drew, Yvette
author_sort Drew, Yvette
collection PubMed
description The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer.
format Online
Article
Text
id pubmed-4816267
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48162672016-12-15 The development of PARP inhibitors in ovarian cancer: from bench to bedside Drew, Yvette Br J Cancer Minireview The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer. Nature Publishing Group 2015-12-15 2015-12-15 /pmc/articles/PMC4816267/ /pubmed/26669452 http://dx.doi.org/10.1038/bjc.2015.394 Text en Copyright © 2015 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Drew, Yvette
The development of PARP inhibitors in ovarian cancer: from bench to bedside
title The development of PARP inhibitors in ovarian cancer: from bench to bedside
title_full The development of PARP inhibitors in ovarian cancer: from bench to bedside
title_fullStr The development of PARP inhibitors in ovarian cancer: from bench to bedside
title_full_unstemmed The development of PARP inhibitors in ovarian cancer: from bench to bedside
title_short The development of PARP inhibitors in ovarian cancer: from bench to bedside
title_sort development of parp inhibitors in ovarian cancer: from bench to bedside
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816267/
https://www.ncbi.nlm.nih.gov/pubmed/26669452
http://dx.doi.org/10.1038/bjc.2015.394
work_keys_str_mv AT drewyvette thedevelopmentofparpinhibitorsinovariancancerfrombenchtobedside
AT drewyvette developmentofparpinhibitorsinovariancancerfrombenchtobedside

Ejemplares similares